Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 152

Results For "Oval"

2717 News Found

Ichnos Glenmark Innovation receives USFDA fast track designation for ISB 2001 for relapsed/refractory multiple myeloma
News | May 06, 2025

Ichnos Glenmark Innovation receives USFDA fast track designation for ISB 2001 for relapsed/refractory multiple myeloma

IGI recently completed the dose-escalation portion of its Phase 1 clinical study in patients with heavily pretreated multiple myeloma


SMS Pharmaceuticals’ Vizag plant receives WHO Geneva prequalification
News | May 03, 2025

SMS Pharmaceuticals’ Vizag plant receives WHO Geneva prequalification

This significant milestone enhances our global regulatory standing


CHMP recommends EU label update for Roche’s Phesgo to allow administration outside of clinical settings
Clinical Trials | May 01, 2025

CHMP recommends EU label update for Roche’s Phesgo to allow administration outside of clinical settings

Phesgo label expansion delivers on patients’ preference for at-home administration and is an important step in freeing up cancer care capacity in clinical settings


Aster DM Healthcare completes acquisition of 5% stake in Quality Care India
News | May 01, 2025

Aster DM Healthcare completes acquisition of 5% stake in Quality Care India

The transaction structured as share swap, is valued at ~Rs. 849 crore, with no cash outflow


Medanta to set up a 400-bed super specialty hospital in Guwahati
Healthcare | April 30, 2025

Medanta to set up a 400-bed super specialty hospital in Guwahati

The Board has also approved plans to invest approximately Rs. 500 crores including cost of land in developing a state-of-the-art, 400-bed super specialty hospital


Vimta Labs to invest Rs. 50 crores to Biologics CDMO business foray
News | April 29, 2025

Vimta Labs to invest Rs. 50 crores to Biologics CDMO business foray

The foray into this new segment will help Vimta to enter into the growing CDMO business of biologics and peptides


Merck to acquire US Biopharma firm SpringWorks Therapeutics for enterprise value of $3.4 billion
Biopharma | April 28, 2025

Merck to acquire US Biopharma firm SpringWorks Therapeutics for enterprise value of $3.4 billion

Planned acquisition will strengthen the presence of Merck Healthcare in the United States and expand reach of SpringWorks’ therapeutic innovations to more patients with rare tumors worldwide


Biocon Biologics receives positive CHMP opinions for biosimilar Denosumab in Europe
Drug Approval | April 28, 2025

Biocon Biologics receives positive CHMP opinions for biosimilar Denosumab in Europe

The positive opinions are based on applications submitted by Biosimilar Collaborations Ireland Limited


CuraTeQ Biologics receives positive opinion for biosimilar Dazublys from EMA
Drug Approval | April 28, 2025

CuraTeQ Biologics receives positive opinion for biosimilar Dazublys from EMA

Trastuzumab specifically binds and inhibits the human epidermal growth factor receptor 2 (HER2) protein